Neovasculogenic therapy to augment perfusion and preserve viability in ischemic cardiomyopathy.
about
Computational protein design to reengineer stromal cell-derived factor-1α generates an effective and translatable angiogenic polypeptide analog.Stromal cell-derived factor-1 enhances pro-angiogenic effect of granulocyte-colony stimulating factor.Spatially oriented, temporally sequential smooth muscle cell-endothelial progenitor cell bi-level cell sheet neovascularizes ischemic myocardium.Sustained release of engineered stromal cell-derived factor 1-α from injectable hydrogels effectively recruits endothelial progenitor cells and preserves ventricular function after myocardial infarction.Mathematically engineered stromal cell-derived factor-1α stem cell cytokine analog enhances mechanical properties of infarcted myocardium.Spliced stromal cell-derived factor-1α analog stimulates endothelial progenitor cell migration and improves cardiac function in a dose-dependent manner after myocardial infarctionMyocardial tissue elastic properties determined by atomic force microscopy after stromal cell-derived factor 1α angiogenic therapy for acute myocardial infarction in a murine model.Stromal cell-derived factor-1alpha activation of tissue-engineered endothelial progenitor cell matrix enhances ventricular function after myocardial infarction by inducing neovasculogenesis.Oxygen-dependent quenching of phosphorescence used to characterize improved myocardial oxygenation resulting from vasculogenic cytokine therapyAcute myocardial rescue with endogenous endothelial progenitor cell therapy.Biochemically engineered stromal cell-derived factor 1-alpha analog increases perfusion in the ischemic hind limb.Cardiac retransplantation is an efficacious therapy for primary cardiac allograft failure.Smooth muscle cell sheet transplantation preserve cardiac function and minimize cardiac remodeling in a rat myocardial infarction model.Transplantation of endothelial progenitor cells as therapeutics for cardiovascular diseases.Re-engineered stromal cell-derived factor-1α and the future of translatable angiogenic polypeptide design.Tissue-engineered pro-angiogenic fibroblast scaffold improves myocardial perfusion and function and limits ventricular remodeling after infarction.Regenerative cell therapy and pharmacotherapeutic intervention in heart failure: Part 2: Pharmacological targets, agents and intervention perspectives.The potential of statin and stromal cell-derived factor-1 to promote angiogenesis.Progesterone modulates endothelial progenitor cell (EPC) viability through the CXCL12/CXCR4/PI3K/Akt signalling pathway.
P2860
Q30406999-5536F496-DF3E-4A79-A7CE-5A1D74D59126Q33270596-C4A65D0B-91B7-4DE5-8FA1-7A66031DDDF2Q33951294-FD5E0E4D-577A-4418-B76D-7B679D6E0A1EQ33951374-79AC853E-3041-4ED1-B7D3-AF138C3AB72DQ34050245-26815D95-5300-47BE-8521-BA97773FD31DQ34056983-3D9E983A-8AB6-42B9-8973-BB54229AEC63Q34140398-2B83E57B-E0EC-4025-B853-FEDE00A54F51Q34140763-7C14C074-221F-40FB-8CE5-D3098FDBACA3Q34994620-6EF0DC38-1856-4C58-9E35-E74C3EAC4D81Q35607069-ABFF3EA8-B8AE-488F-BB1E-A4C218147BA1Q35776071-EC9BB39F-AF85-4BBE-B242-98397534F230Q36728769-BBB155D5-B07A-4BAB-890B-CA8FA7E3B400Q37154181-CCE34040-4CD8-4C30-BE81-E9C06C0E60A1Q37570669-7694F117-EFD0-4E25-A513-5B7595856A9CQ38035620-ABD5BA29-AB87-47BF-8C8B-AFF7954D0FF3Q39926866-C0EBB461-3563-4E56-92B4-4FBF4117212FQ43251940-FA4CB386-1BC2-4246-98BC-F724523B0690Q46170604-4FB1AA34-AA47-4AEF-BBFE-DC8120AEBD72Q48946164-F67561E3-8CF1-44DA-BD57-D46C406600CC
P2860
Neovasculogenic therapy to augment perfusion and preserve viability in ischemic cardiomyopathy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Neovasculogenic therapy to aug ...... ty in ischemic cardiomyopathy.
@en
Neovasculogenic therapy to aug ...... ty in ischemic cardiomyopathy.
@nl
type
label
Neovasculogenic therapy to aug ...... ty in ischemic cardiomyopathy.
@en
Neovasculogenic therapy to aug ...... ty in ischemic cardiomyopathy.
@nl
prefLabel
Neovasculogenic therapy to aug ...... ty in ischemic cardiomyopathy.
@en
Neovasculogenic therapy to aug ...... ty in ischemic cardiomyopathy.
@nl
P2093
P1476
Neovasculogenic therapy to aug ...... ty in ischemic cardiomyopathy.
@en
P2093
Corinna M Panlilio
Danielle A Murphy
Erik E Suarez
George P Liao
H Lee Sweeney
Jeffrey E Cohen
Kevin J Morine
Mark F Berry
Matthew J Leskowitz
Pavan Atluri
P304
P356
10.1016/J.ATHORACSUR.2005.12.015
P407
P577
2006-05-01T00:00:00Z